210 related articles for article (PubMed ID: 33259959)
1. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
[TBL] [Abstract][Full Text] [Related]
3. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
4. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
[TBL] [Abstract][Full Text] [Related]
5. SHH inhibitors for the treatment of medulloblastoma.
Samkari A; White J; Packer R
Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
[TBL] [Abstract][Full Text] [Related]
6. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D
Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892
[TBL] [Abstract][Full Text] [Related]
7. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
[TBL] [Abstract][Full Text] [Related]
8. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
Climans SA; Macdonald DR; Sutherland DE; Mason WP
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
De Smaele E; Ferretti E; Gulino A
Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
[TBL] [Abstract][Full Text] [Related]
11. Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis.
Lou E; Nelson AC; Kool M
Cancer Biol Ther; 2019; 20(11):1398-1402. PubMed ID: 31423907
[TBL] [Abstract][Full Text] [Related]
12. Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma.
Kim J; Dey A; Malhotra A; Liu J; Ahn SI; Sei YJ; Kenney AM; MacDonald TJ; Kim Y
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24205-24212. PubMed ID: 32934143
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
[TBL] [Abstract][Full Text] [Related]
14. Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
Roesler R; de Farias CB; Brunetto AT; Gregianin L; Jaeger M; Nör C; Thomaz A
Neuro Oncol; 2022 Jul; 24(7):1210-1211. PubMed ID: 35552442
[No Abstract] [Full Text] [Related]
15. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
16. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib.
Rudin CM
Clin Cancer Res; 2012 Jun; 18(12):3218-22. PubMed ID: 22679179
[TBL] [Abstract][Full Text] [Related]
18. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
20. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma.
Infante P; Malfanti A; Quaglio D; Balducci S; De Martin S; Bufalieri F; Mastrotto F; Basili I; Garofalo M; Lospinoso Severini L; Mori M; Manni I; Moretti M; Nicoletti C; Piaggio G; Caliceti P; Botta B; Ghirga F; Salmaso S; Di Marcotullio L
Cancer Lett; 2021 Feb; 499():220-231. PubMed ID: 33249196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
